Home › Soft Tissue Sarcoma › NCT04719156
Fluorescent Intra-operative Tumor Margin Examination
Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging
Who can join
Ages 18 to 100 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients above the age of 18 with a primary musculoskeletal tumor that has been indicated for surgical excision by a fellowship trained orthopaedic oncologist. * Surgical consent was obtained prior to research consent. * Patients with a biopsy-confirmed primary soft tissue or bone tumor that has not been previously excised and has a known risk of local or remote recurrence. Exclusion Criteria: * Patients below the age of 18 * Pregnancy, breast feeding * Patients with a history of anaphylactic reaction to contrast media or fluorescein allergy * Prior surgery local to the mass being excised * Non- or minimally-recurrent masses (i.e. osteochondroma) * Dialysis, renal failure, uremia
About the study
Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.
What is being tested
- Indocyanine green solution administered at 2.0mg/kg. (drug)
- Stryker SPY-PHI Imaging Device (device)
Sponsor: Kurt Weiss · Participants: 110 · Started: Mar 2, 2021
Contact the study team
- Beata Krawczyk, [email protected] · Phone: 412-401-3000
- Kurt Weiss, MD · Phone: 4128024100
Official record on ClinicalTrials.gov — NCT04719156
Locations in the U.S.
| Pennsylvania | UPMC-Shadyside Hospital, Pittsburgh |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.